PMID- 29524187
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240330
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 9
IP  - 2
DP  - 2018 Apr
TI  - Factors That Influence Pancreatic Beta Cell Function and Insulin Resistance in 
      Newly Diagnosed Type 2 Diabetes Patients: A Sub-Analysis of the MARCH Trial.
PG  - 743-752
LID - 10.1007/s13300-018-0393-5 [doi]
AB  - INTRODUCTION: The Metformin and Acarbose in Chinese as the initial Hypoglycemic 
      treatment (MARCH) trial has demonstrated a similar efficacy in HbA1c reduction 
      between acarbose and metformin treatments in newly diagnosed type 2 diabetes 
      mellitus (T2DM) patients. The current sub-analysis of the MARCH trail aims to 
      evaluate the baseline characteristics that may influence the improvement of 
      pancreatic beta-cell function and insulin resistance after acarbose therapy in 
      Chinese patients with newly diagnosed T2DM. METHODS: Of the 784 patients who 
      entered the MARCH trail, 391 were assigned to the acarbose therapy group; 304 of 
      these completed 48 weeks of follow-up of acarbose therapy. At 48 weeks, on the 
      basis of the tertiles of change in homeostasis model assessment-beta cell 
      function (∆HOMA-beta) and homeostasis model assessment-insulin resistance 
      (∆HOMA-IR), the subjects were divided into lowly, mediumly, and highly improved 
      groups. RESULTS: In the highly improved HOMA-beta group, patients had higher 
      systolic blood pressure (SBP), 2-h postprandial blood glucose (PBG), hemoglobin 
      A1c (HbA1c), and lower high-density lipoprotein cholesterol (HDL-c), fasting 
      serum insulin (FINS) concentration, and HOMA-IR in comparison to the lowly 
      improved group (p < 0.05). A positive correlation was observed between HbA1c, 
      SBP, and highly improved ∆HOMA-beta (p < 0.05), while an inverse correlation was 
      evident between HDL-c and highly improved ∆HOMA-beta (p < 0.05). The highly improved 
      HOMA-IR group had a significantly higher body mass index (BMI), fasting blood 
      glucose (FBG), FINS concentration, and HOMA-beta in comparison to the lowly improved 
      group (p < 0.05). A positive correlation was observed between FBG, waist 
      circumference, and highly improved HOMA-IR (p < 0.05). CONCLUSION: Newly 
      diagnosed T2DM Chinese patients with lower baseline HDL-c and higher HbA1c and 
      SBP values are more likely to achieve improvement in beta cell function whereas 
      baseline fasting blood glucose and waist circumference were the significant 
      factors associated with improvement in insulin resistance with acarbose therapy. 
      TRIAL REGISTRATION: The clinical trial registry number was ChiCTR-TRC-08000231.
FAU - Duan, Yan
AU  - Duan Y
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, 100020, People's Republic of China.
FAU - Liu, Jia
AU  - Liu J
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, 100020, People's Republic of China.
FAU - Xu, Yuan
AU  - Xu Y
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, 100020, People's Republic of China.
FAU - Yang, Ning
AU  - Yang N
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, 100020, People's Republic of China.
FAU - Yang, Wenying
AU  - Yang W
AD  - Department of Endocrinology, China-Japan Friendship Hospital, Beijing, 100029, 
      People's Republic of China. ywying_1010@163.com.
FAU - Wang, Guang
AU  - Wang G
AUID- ORCID: 0000-0002-3810-1419
AD  - Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical 
      University, Beijing, 100020, People's Republic of China. drwg6688@126.com.
LA  - eng
GR  - Z161100000516069/Capital Clinical Research Foundation of Beijing Municipal 
      Commission of Science and Technology/
GR  - 81600657/Chinese National Natural Science Foundation/
GR  - QML20150308/Beijing Municipal Administration of Hospitals' Youth Programme/
PT  - Journal Article
DEP - 20180309
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6104271
OTO - NOTNLM
OT  - Acarbose
OT  - Beta cell function
OT  - Diabetes
OT  - HOMA-IR
OT  - HOMA-beta
OT  - Insulin resistance
EDAT- 2018/03/11 06:00
MHDA- 2018/03/11 06:01
PMCR- 2018/03/09
CRDT- 2018/03/11 06:00
PHST- 2017/12/26 00:00 [received]
PHST- 2018/03/11 06:00 [pubmed]
PHST- 2018/03/11 06:01 [medline]
PHST- 2018/03/11 06:00 [entrez]
PHST- 2018/03/09 00:00 [pmc-release]
AID - 10.1007/s13300-018-0393-5 [pii]
AID - 393 [pii]
AID - 10.1007/s13300-018-0393-5 [doi]
PST - ppublish
SO  - Diabetes Ther. 2018 Apr;9(2):743-752. doi: 10.1007/s13300-018-0393-5. Epub 2018 
      Mar 9.